Sionna to advance SION-451 plus SION-2222 into Phase 2a after PreciSION CF post hoc analysis
The company also cut its workforce by about 46% and now projects cash runway into the second half of 2029.
SEC filing
Latest
4 stories
Monday, September 14
Tuesday, August 11
Immunic adds Elena Ridloff to board ahead of Phase 3 MS readout
The company also detailed the separation terms for former CEO Daniel Vitt as he transitions to a consulting and advisory role.
SEC filing
Monday, August 10
Sionna's SION-719 misses key endpoint in Phase 2a cystic fibrosis trial
The company will not advance SION-719 as an add-on to standard of care, while a separate Phase 1 trial identified SION-451 plus SION-2222 as its preferred dual combination.
SEC filing
Thursday, August 6
Sionna keeps two CF trial readouts on track for summer 2026
Sionna Therapeutics says its Phase 2a trial of SION-719 and its Phase 1 dual-combination trial with SION-451 both remain on schedule to deliver topline data this summer.
SEC filing